Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Clinical and genetic analysis of melanomas arising in acral sites.

Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I.

Eur J Cancer. 2019 Aug 13;119:66-76. doi: 10.1016/j.ejca.2019.07.008. [Epub ahead of print]

PMID:
31419753
2.

Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.

Vogel FCE, Bordag N, Zügner E, Trajkovic-Arsic M, Chauvistré H, Shannan B, Váraljai R, Horn S, Magnes C, Thomas Siveke J, Schadendorf D, Roesch A.

J Invest Dermatol. 2019 Jun 21. pii: S0022-202X(19)31782-8. doi: 10.1016/j.jid.2019.06.124. [Epub ahead of print]

PMID:
31229500
3.

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Zaremba A, Chorti E, Jockenhöfer F, Bolz S, Sirin S, Glas M, Becker JC, Ugurel S, Roesch A, Schadendorf D, Livingstone E, Hagenacker T, Zimmer L.

J Immunother Cancer. 2019 May 29;7(1):141. doi: 10.1186/s40425-019-0626-9.

4.

Implementing Pre-exposure Prophylaxis for HIV Prevention at an Urban Youth Clinic.

Roesch A.

J Assoc Nurses AIDS Care. 2019 Mar-Apr;30(2):232-237. doi: 10.1097/JNC.0000000000000039. No abstract available.

PMID:
30822295
5.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.

PMID:
30721788
6.

Quantitative EEG and Verbal Fluency in DBS Patients: Comparison of Stimulator-On and -Off Conditions.

Hatz F, Meyer A, Roesch A, Taub E, Gschwandtner U, Fuhr P.

Front Neurol. 2019 Jan 9;9:1152. doi: 10.3389/fneur.2018.01152. eCollection 2018.

7.

Melanoma.

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S.

Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Review. Erratum in: Lancet. 2019 Feb 23;393(10173):746.

PMID:
30238891
8.

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Kunz M, Löffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, Kottek T, Nickel B, Hopp L, Landsberg J, Hoffmann S, Tüting T, Zigrino P, Mauch C, Utikal J, Ziemer M, Schulze HJ, Hölzel M, Roesch A, Kneitz S, Meierjohann S, Bosserhoff A, Binder H, Schartl M.

Oncogene. 2018 Nov;37(47):6136-6151. doi: 10.1038/s41388-018-0385-y. Epub 2018 Jul 11.

PMID:
29995873
9.

[What do migraine apps offer?]

Dahlem MA, Roesch A, Neeb L, Kropp P, Dresler T.

MMW Fortschr Med. 2018 Feb;160(2):51-54. doi: 10.1007/s15006-018-0153-5. Review. German. No abstract available.

PMID:
29417508
10.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

11.

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.

Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. No abstract available.

PMID:
28735071
12.

Actinic keratoses treated with cold atmospheric plasma.

Wirtz M, Stoffels I, Dissemond J, Schadendorf D, Roesch A.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e37-e39. doi: 10.1111/jdv.14465. Epub 2017 Jul 31. No abstract available.

PMID:
28695987
13.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kähler KC, Gesierich A, Meissner M, von Bubnoff D, Göppner D, Schlaak M, Pföhler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C.

Eur J Cancer. 2017 Aug;81:36-44. doi: 10.1016/j.ejca.2017.05.014. Epub 2017 Jun 7.

PMID:
28600969
14.

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.

Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Mohr P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A.

Oncotarget. 2017 Jun 20;8(25):40683-40692. doi: 10.18632/oncotarget.16542.

15.

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT.

Clin Cancer Res. 2017 Jun 15;23(12):3181-3190. doi: 10.1158/1078-0432.CCR-17-0201. Epub 2017 Feb 23.

16.

Fine Motor Function Skills in Patients with Parkinson Disease with and without Mild Cognitive Impairment.

Dahdal P, Meyer A, Chaturvedi M, Nowak K, Roesch AD, Fuhr P, Gschwandtner U.

Dement Geriatr Cogn Disord. 2016;42(3-4):127-134. Epub 2016 Sep 20.

PMID:
27643700
17.

Immunotherapy in melanoma: Recent advances and future directions.

Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D.

Eur J Surg Oncol. 2017 Mar;43(3):604-611. doi: 10.1016/j.ejso.2016.07.145. Epub 2016 Sep 2. Review.

PMID:
27769635
18.

Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.

Herz S, Höfer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, Ugurel S, Roesch A, Livingstone E, Schilling B, Franklin C.

Eur J Cancer. 2016 Nov;67:66-72. doi: 10.1016/j.ejca.2016.07.026. Epub 2016 Sep 8.

PMID:
27614165
19.

JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers.

Facompre ND, Harmeyer KM, Sole X, Kabraji S, Belden Z, Sahu V, Whelan K, Tanaka K, Weinstein GS, Montone KT, Roesch A, Gimotty PA, Herlyn M, Rustgi AK, Nakagawa H, Ramaswamy S, Basu D.

Cancer Res. 2016 Sep 15;76(18):5538-49. doi: 10.1158/0008-5472.CAN-15-3377. Epub 2016 Aug 3. Erratum in: Cancer Res. 2017 Dec 15;77(24):7136.

20.

Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis.

Sondermann W, Zimmer L, Schadendorf D, Roesch A, Klode J, Dissemond J.

Medicine (Baltimore). 2016 Jul;95(29):e4332. doi: 10.1097/MD.0000000000004332.

21.

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A.

Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3.

22.

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.

Roesch A, Paschen A, Landsberg J, Helfrich I, Becker JC, Schadendorf D.

Eur J Cancer. 2016 May;59:109-112. doi: 10.1016/j.ejca.2016.02.023. Epub 2016 Mar 26.

PMID:
27023049
24.

The role of Orai-STIM calcium channels in melanocytes and melanoma.

Stanisz H, Vultur A, Herlyn M, Roesch A, Bogeski I.

J Physiol. 2016 Jun 1;594(11):2825-35. doi: 10.1113/JP271141. Epub 2016 Apr 6. Review.

25.

Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging.

Stoffels I, Morscher S, Helfrich I, Hillen U, Leyh J, Burton NC, Sardella TC, Claussen J, Poeppel TD, Bachmann HS, Roesch A, Griewank K, Schadendorf D, Gunzer M, Klode J.

Sci Transl Med. 2015 Dec 9;7(317):317ra199. doi: 10.1126/scitranslmed.aad1278. Erratum in: Sci Transl Med. 2015 Dec 23;7(319):319er8. Lehy, Julia [corrected to Leyh, Julia].

PMID:
26659573
26.

Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012.

Jockenhöfer F, Klode J, Kröger K, Roesch A, Al Ghazal P, Dissemond J.

Int Wound J. 2016 Oct;13(5):951-6. doi: 10.1111/iwj.12463. Epub 2015 Aug 6.

PMID:
26250591
27.

Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.

Livingstone E, Swann S, Lilla C, Schadendorf D, Roesch A.

Exp Dermatol. 2015 Sep;24(9):709-10. doi: 10.1111/exd.12718. Epub 2015 May 8. No abstract available.

PMID:
25865258
28.

Contrasting responses of Central Asian rock glaciers to global warming.

Sorg A, Kääb A, Roesch A, Bigler C, Stoffel M.

Sci Rep. 2015 Feb 6;5:8228. doi: 10.1038/srep08228.

29.

Melanoma stem cells.

Roesch A.

J Dtsch Dermatol Ges. 2015 Feb;13(2):118-24. doi: 10.1111/ddg.12584. Review. English, German.

PMID:
25631128
30.

Melanoma.

Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A.

Nat Rev Dis Primers. 2015 Apr 23;1:15003. doi: 10.1038/nrdp.2015.3. Review.

PMID:
27188223
31.

Aetiology, comorbidities and cofactors of chronic leg ulcers: retrospective evaluation of 1 000 patients from 10 specialised dermatological wound care centers in Germany.

Jockenhöfer F, Gollnick H, Herberger K, Isbary G, Renner R, Stücker M, Valesky E, Wollina U, Weichenthal M, Karrer S, Kuepper B, Roesch A, Dissemond J.

Int Wound J. 2016 Oct;13(5):821-8. doi: 10.1111/iwj.12387. Epub 2014 Dec 5.

PMID:
25483380
32.

Bacterial spectrum colonizing chronic leg ulcers: a 10-year comparison from a German wound care center.

Jockenhöfer F, Chapot V, Stoffels-Weindorf M, Körber A, Klode J, Buer J, Küpper B, Roesch A, Dissemond J.

J Dtsch Dermatol Ges. 2014 Dec;12(12):1121-7. doi: 10.1111/ddg.12540. English, German.

PMID:
25482696
33.

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.

Cierlitza M, Chauvistré H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, Vogt T, Roesch A.

Exp Dermatol. 2015 Feb;24(2):155-7. doi: 10.1111/exd.12613.

34.

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.

Roesch A.

Oncogene. 2015 Jun 4;34(23):2951-7. doi: 10.1038/onc.2014.249. Epub 2014 Aug 11. Review.

PMID:
25109330
35.

Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry.

Stanisz H, Saul S, Müller CS, Kappl R, Niemeyer BA, Vogt T, Hoth M, Roesch A, Bogeski I.

Pigment Cell Melanoma Res. 2014 May;27(3):442-53. doi: 10.1111/pcmr.12222. Epub 2014 Mar 7.

PMID:
24472175
36.

[Association of Dermatologic Oncology (ADO)].

Roesch A, Weber C.

J Dtsch Dermatol Ges. 2014 Jan;12(1):96-7. doi: 10.1111/ddg.12283. German. No abstract available.

PMID:
24393325
37.

'TWIST and switch' metastasis.

Roesch A.

Pigment Cell Melanoma Res. 2014 Mar;27(2):157-8. doi: 10.1111/pcmr.12198. Epub 2013 Dec 16. No abstract available.

PMID:
24283630
38.

SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway.

Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T, Xu X, Hwang WT, Lieu M, Belser E, Liu R, Somasundaram R, Herlyn M, Kaufman RE.

J Invest Dermatol. 2014 Apr;134(4):1108-1118. doi: 10.1038/jid.2013.437. Epub 2013 Oct 24.

39.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F.

Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3.

40.

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, Vogt T, Herlyn M.

Cancer Cell. 2013 Jun 10;23(6):811-25. doi: 10.1016/j.ccr.2013.05.003.

41.

Transcriptional profiling of human endogenous retrovirus group HERV-K(HML-2) loci in melanoma.

Schmitt K, Reichrath J, Roesch A, Meese E, Mayer J.

Genome Biol Evol. 2013;5(2):307-28. doi: 10.1093/gbe/evt010.

42.

Cancer stem cell definitions and terminology: the devil is in the details.

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C.

Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. Review.

PMID:
23051844
43.

From cancer stem cells to tumor maintenance in melanoma.

Fukunaga-Kalabis M, Roesch A, Herlyn M.

J Invest Dermatol. 2011 Aug;131(8):1600-4. doi: 10.1038/jid.2011.159. Epub 2011 Jun 9.

44.

In vivo and ex vivo MR imaging of slowly cycling melanoma cells.

Magnitsky S, Roesch A, Herlyn M, Glickson JD.

Magn Reson Med. 2011 Nov;66(5):1362-73. doi: 10.1002/mrm.22917. Epub 2011 Apr 26.

45.

Identification of new genes associated with melanoma.

Mauerer A, Roesch A, Hafner C, Stempfl T, Wild P, Meyer S, Landthaler M, Vogt T.

Exp Dermatol. 2011 Jun;20(6):502-7. doi: 10.1111/j.1600-0625.2011.01254.x. Epub 2011 Mar 16.

PMID:
21410771
46.

Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population.

Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M.

Oncogene. 2010 Nov 18;29(46):6115-24. doi: 10.1038/onc.2010.350. Epub 2010 Aug 23.

47.

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M.

Cell. 2010 May 14;141(4):583-94. doi: 10.1016/j.cell.2010.04.020.

48.

Sterically hindered benzophenones via rhodium-catalyzed oxidative arylation of aldehydes.

Chuzel O, Roesch A, Genet JP, Darses S.

J Org Chem. 2008 Oct 3;73(19):7800-2. doi: 10.1021/jo801460w. Epub 2008 Aug 28.

PMID:
18754578
49.

Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.

Roesch A, Boerzsoenyi J, Babilas P, Landthaler M, Szeimies RM.

J Dtsch Dermatol Ges. 2008 Apr;6(4):292-7. Epub 2007 Nov 27. English, German.

PMID:
18042250
50.

Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating nevi and metastatic vertical growth phase melanoma.

Roesch A, Becker B, Bentink S, Spang R, Vogl A, Hagen I, Landthaler M, Vogt T.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2486-90.

Supplemental Content

Loading ...
Support Center